Cagrilintide + Semaglutide: CagriSema reference
The Aminos CagriSema listing names cagrilintide and semaglutide. A catalogue blend with those names is not automatically equivalent to the coadministered agents in a clinical trial.
Reviewed September 2026
- Residues
- Multiple components. not applicable: A single residue count is not defined for a mixture; component counts must not be summed into a fictitious peptide.
- Average mass
- Mixture-dependent. not applicable: There is no single molecular mass for this blend. Component molecular masses are separate properties, not a summed or arbitrary average blend mass.
- pI
- Not applicable. not applicable: A mixture has no unique single-peptide pI. Component pI values, mixture electrophoretic behavior and solution pH are distinct.
Reference details
| Residues | Multiple components |
|---|---|
| Average mass | Mixture-dependent |
| pI | Not applicable |
| Research area | Metabolic, Multi-component blends |
|---|
Property basis and sources
These describe the reference compound or formulation, not identification or testing of the supplied lot.
Multi-component blend as designated by the reference title; not one covalently connected peptide. Component identity, proportions, salts and compatibility are not verified by component papers.
- Residues: Multiple components (not applicable). A single residue count is not defined for a mixture; component counts must not be summed into a fictitious peptide. Residues source 1
- Average mass: Mixture-dependent (not applicable). There is no single molecular mass for this blend. Component molecular masses are separate properties, not a summed or arbitrary average blend mass. Average mass source 1
- pI: Not applicable (not applicable). A mixture has no unique single-peptide pI. Component pI values, mixture electrophoretic behavior and solution pH are distinct. pI source 1
Reference scope and linked records
Reference type: Multi-component blend.
This is a research-reference entry, not a product certificate, treatment recommendation or administration guide. The sources below describe their own materials and methods. Catalogue identity, lot testing and clinical evidence are separate questions.
Catalogue context: Cagrilintide + Semaglutide (CagriSema). The product retains its own name and specification; this link does not certify equivalence to published study material.
Related references
Sources and their scope
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. Source for the chemistry or study context discussed above; not an Aminos lot certificate.
- Development of Cagrilintide, a Long-Acting Amylin Analogue. Source for the chemistry or study context discussed above; not an Aminos lot certificate.
- Discovery of the Once-Weekly GLP-1 Analogue Semaglutide. Source for the chemistry or study context discussed above; not an Aminos lot certificate.
Source check: 26 September 2026. This is an editorial source check, not a claim of independent clinical or laboratory review.
About Cagrilintide + Semaglutide: CagriSema reference
Identity and context
Cagrilintide is an amylin analogue and semaglutide a GLP-1 analogue. They remain separate molecular identities when combined. The product label does not establish the amount of each component, their ratio or equivalence to a studied preparation.
Reference classification
Multi-component blend. The linked catalogue product is Cagrilintide + Semaglutide (CagriSema). This reference does not independently authenticate the material supplied.
Storage and handling
Analytical specification
Request both ingredient amounts, chemical forms and mixture-specific analytical and stability documentation. Do not interpret total blend mass as the amount of each ingredient or assume the trial formulation can be reconstructed from a product name.
Storage and experimental handling
Use the documented conditions for the actual chemical form and preparation. No universal storage temperature, expiry or solution shelf life is assigned here. Follow the lot documentation, safety data sheet and validated laboratory protocol; this page is not a reconstitution or administration guide.
Research evidence
| Area | Summary | Evidence |
|---|---|---|
| What the source examines | The REDEFINE 1 primary publication reports a randomized phase 3a study of coadministered cagrilintide and semaglutide in adults with overweight or obesity. It measured body-weight outcomes and safety against defined comparator groups. Its preparation, population and study design are part of the evidence. | Source context |
| What cannot be inferred | The trial does not test the Aminos mixture. Sharing a combination name does not establish pharmaceutical equivalence, manufacturing quality or a safe administration regimen. The individual component papers likewise cannot verify the finished mixture. | Evidence limits |
References
Sources used for the data on this page, checked September 2026.
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or ObesityPrimary source for the reference discussion; not lot-specific product evidence.
- Development of Cagrilintide, a Long-Acting Amylin AnaloguePrimary source for the reference discussion; not lot-specific product evidence.
- Discovery of the Once-Weekly GLP-1 Analogue SemaglutidePrimary source for the reference discussion; not lot-specific product evidence.
Reference information only. This page describes the chemistry and published research context of a laboratory compound. Nothing here is medical or dosing advice. Aminos compounds are for laboratory research use only and are not medicines.